Magellan Health Collaborates with Bayer to Educate Members and Clinicians about Availability of Long-Acting Reversible Contraceptives

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Magellan
Health, Inc.
(NASDAQ: MGLN) announced today that it has
collaborated with Bayer to launch an education initiative
designed to focus on women’s health and reduce the rate of unintended
pregnancies through the appropriate utilization of long-acting
reversible contraceptives (LARC). Magellan Healthcare has launched an
outreach campaign to improve education about and access to the full
range of contraceptive methods for Magellan Complete Care of Florida
members. In addition, in collaboration with Bayer, Magellan Rx
Management, which provides pharmacy benefit management services for
Magellan Complete Care of Florida, is utilizing advanced analytics to
conduct intensified physician and member outreach and education to
improve contraceptive utilization, including LARC therapy.

“Magellan Health continues to focus on innovative, member-centric
programs, and this initiative represents another way in which Magellan
is using its clinical innovation capabilities and data analytics to help
improve member satisfaction and health, while reducing cost,” said Dr.
Karen Amstutz, chief medical officer of Magellan Health. “By educating
women and providers about the numerous choices they have across the
contraceptive market, we’re helping members make the best choice for
themselves and their health.

“As a leader in women’s health, Bayer is committed to increasing
awareness of highly effective birth control options like intrauterine
devices (IUDs) for women who can benefit from them,” said Paul Bedard,
senior vice president and general manager of Bayer’s Women’s Healthcare
division. “Through this innovative collaboration with Magellan, we hope
to help ensure that women and their physicians have the information they
need to make informed decisions about the most appropriate contraceptive
methods to meet their individual needs.”

According to the Centers for Disease Control and Prevention (CDC),
approximately 50 percent of pregnancies are unintended, costing $21
billion annually in the United States alone. The Centers for Medicare &
Medicaid Services (CMS) has urged Medicaid programs to adopt policies
intended to increase the number of patients utilizing LARC due to the
multiple clinical, economic, and patient satisfaction benefits.

About Magellan Health: Headquartered in Scottsdale, Ariz., Magellan
Health, Inc.
is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
develops innovative solutions that combine advanced analytics, agile
technology and clinical excellence to drive better decision making,
positively impact health outcomes and optimize the cost of care for the
members we serve — all within a customer-first culture. Magellan’s
customers include health plans and other managed care organizations,
employers, labor unions, various military and governmental agencies and
third-party administrators. For more information, visit MagellanHealth.com.

About Bayer: Bayer is a global enterprise with core competencies
in the Life Science fields of health care and agriculture. Its products
and services are designed to benefit people and improve their quality of
life. At the same time, the Group aims to create value through
innovation, growth and high earning power. Bayer is committed to the
principles of sustainable development and to its social and ethical
responsibilities as a corporate citizen. In fiscal 2015, the Group
employed around 117,000 people and had sales of EUR 46.3 billion.
Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR
4.3 billion. These figures include those for the high-tech polymers
business, which was floated on the stock market as an independent
company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Contacts

Magellan Health, Inc.
Media Contact:
Colleen Flanagan
Johnson, 860-507-1923
cefjohnson@magellanhealth.com
or
Investor
Contact:

Renie Shapiro Silver, 877-645-6464
rshapiro@magellanhealth.com